micro-community-banner
 
  • Saved

1yr
Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan's role in advancing chemotherapy - PubMed

Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan's role in advancing chemotherapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39238964/

In conclusion, Sacituzumab Govitecan shows potential as an innovative therapeutic option for breast cancer, particularly in metastatic breast cancer and triple-negative breast cancer, but it warrants additional research.

Sacituzumab Govitecan shows potential as an innovative therapeutic option for breast cancer, particularly in metastatic breast cancer and triple-negative breast cancer, but it warrants additional research.

  • Saved

1yr
Elucidating the Intricate Roles of Gut and Breast Microbiomes in Breast Cancer Metastasis to the Bone - PubMed

Elucidating the Intricate Roles of Gut and Breast Microbiomes in Breast Cancer Metastasis to the Bone - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39188104/

The present review describes association of gut and breast microbiomes with bone metastases. We have elaborated on the mechanisms utilized by breast and gut microbiomes that induce breast cancer metastasis,...

This review explores the role of gut and breast microbiomes in breast cancer bone metastasis, highlighting mechanisms and potential therapeutic targets including probiotics, antibiotics, and microbiome modulation to improve survival.

  • Saved

1yr
Comparative complications of prepectoral versus subpectoral breast reconstruction in patients with breast cancer: a meta-analysis - PubMed

Comparative complications of prepectoral versus subpectoral breast reconstruction in patients with breast cancer: a meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39257552/

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024565837, identifier CRD42024565837.

This meta-analysis compares prepectoral (PBR) and subpectoral breast reconstruction (SBR), showing PBR reduces animation deformity but increases the risks of rippling and seroma, with overall comparable complication rates.

  • Saved

1yr
Insights from ESMO 2024: Advances in Breast Oncology

In this video, Dr. Sarah Telaney, a breast medical oncologist at Dana-Farber Cancer Institute, shares key takeaways from ESMO 2024, highlighting three impactful studies in breast oncology. She discusses the promising outcomes of preoperative pembrolizumab for early-stage triple-negative breast cancer, the significant efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-positive disease and brain metastases, and the recently FDA-approved ribociclib for early-stage hormone receptor-positive breast cancer. Dr. Telaney emphasizes the exciting pace of drug development and its potential to improve patient care.

  • Saved

1yr
Comparative complications of prepectoral versus subpectoral breast reconstruction in patients with breast cancer: a meta-analysis - PubMed

Comparative complications of prepectoral versus subpectoral breast reconstruction in patients with breast cancer: a meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39257552/

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024565837, identifier CRD42024565837.